(Azacitidine + cedazuridine) by Taiho Oncology for Myelodysplastic Syndrome: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes